The antidepressant metapramine is a low-affinity antagonist at N-methyl-D-aspartic acid receptors

Neuropharmacology

Volumn 35, Issue 12, 1996, Pages 1703-1707

  Boireau, A ^a   Bordier, F ^a   Durand, G ^a   Doble, A ^a  

^a SANOFI   (France)

Author keywords

3H TCP; antidepressant; cGMP; glutamate; metapramine; NMDA

Indexed keywords

ANTIDEPRESSANT AGENT; CYCLIC GMP; DIZOCILPINE; METAPRAMINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; PHENCYCLIDINE; RADIOLIGAND; TENOCYCLIDINE;

ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; BRAIN SLICE; CONTROLLED STUDY; NEWBORN; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR BINDING;

ANIMALS; ANTIDEPRESSIVE AGENTS, TRICYCLIC; BINDING SITES; BINDING, COMPETITIVE; CELL MEMBRANE; CEREBRAL CORTEX; CYCLIC GMP; DIBENZAZEPINES; DIZOCILPINE MALEATE; GLYCINE; PHENCYCLIDINE; RATS; RATS, INBRED STRAINS; RECEPTORS, N-METHYL-D-ASPARTATE;

EID: 0030513861     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0028-3908(96)00122-0     Document Type: Article

References (28)

1. Boireau A., Garret C., Blanchard J.C. Etude des effets biochimiques d'un nouvel antidépresseur, la métapramine (19560 R.P.), sur l'activité des systèmes dopaminergiques et cholinergiques du striatum du rat. J. Pharmacol. (Paris). 17:1986;75-84.
2. Carlsson M., Carlsson A. Interaction between glutamatergic and monoaminergic systems within the basal ganglia - implication for schizophrenia and Parkinson's Disease. TINS. 13:1990;272-276.
3. Collingridge G.L., Lester R.A.J. Excitatory amino acid receptors in the vertebrate central nervous system. Pharmacol. Rev. 40:1989;143-210.
4. Danysz W., Parsons C.G., Bresink I., Quack G. Glutamate in CNS disorders. DN & P. 8:1995;261-277.
5. Ferrendelli J.A., Kinscherf D.A., Chang M.M. Regulation of levels of guanosine 3′,5′-monophosphate in the central nervous system: effects of depolarizing agents. Mol. Pharmacol. 9:1973;445-454.
6. Fonnum F. Glutamate: a neurotransmitter in mammalian brain. J. Neurochem. 42:1984;1-11.
7. Garthwaite J. Excitatory amino acid receptors and guanosine 3′,5′-cyclic monophosphate in incubated slices of immature and adult rat cerebellum. Neuroscience. 7:1982;2491-2497.
8. Garret C., Scatton B., Julou L. Problèmes méthodologiques posés par l'étude des antidépresseurs. Point de vue pharmacologique et biochimique. Psychol. Méd. 9:1977;293-314.
9. Gee K.R. Therapeutic potential of PCP receptor ligands. Exp. Opin Invest. Drugs. 3:1994;1021-1030.
10. 3H]TCP binding by L-glutamate, glycine, and guanine nucleotides in rat cerebral cortex. Synapse. 8:1991;13-21.
11. Kloog Y., Lamdani-Itkin H., Sokolovsky M. The glycine site of the N-methyl-D-aspartate receptor channel: differences between the binding of HA-966 and of 7-chlorokynurenic acid. J. Neurochem. 54:1990;1576-1583.
12. Krystal J.H., Karper L.P., Seibyl J.P., Freeman G.K., Delaney R., Bremner J.D., Heninger G.R., Bowers M.B., Charney D.S. Subanesthetic effects of the non-competitive NMDA antagonist, ketamine, in humans: psychotomimetic, perceptual, cognitive and neuroendocrine responses. Arch. Gen. Psychiatry. 51:1994;199-214.
13. Luby E.D., Cohen B.D., Rosenbaum G., Gottlieb J.S., Kelly R. Study of a new schizophrenomimetic drug - Sernyl. Arch. Neurol. Psychiatry. 81:1959;363-369.
14. McBain C.J., Mayer M.L. N-methyl-D-aspartic acid receptor structure and function. Physio. Rev. 74:1994;723-760.
15. Muir K.W., Grosset D.G., Gamzu E., Lees K.R. Pharmacological effects of the non-competitive NMDA antagonist CNS 1102 in normal volunteers. Brit. J. Clin. Pharmacol. 38:1994;33-38.
16. Muir K.W., Lees K.L. Clinical experience with excitatory amino acid antagonist drugs. Stroke. 26:1995;503-513.
17. Olney J.W. (1988) Endogenous excitotoxins and neuropathological disorders. In Excitatory Amino Acids in Health and Disease (Lodge D., Ed.), pp. 337-351. John Wiley and Sons, England.
18. Ossowska K. The role of excitatory amino acids in experimental models of Parkinson's disease. J. Neural. Transm. 8:1994;39-71.
19. Oye I., Paulsen O., Maurset A. Effects of ketamine on sensory perception: evidence for a role of N-methyl-D-aspartate receptors. J. Pharmacol. Exp. Ther. 260:1992;1209-1213.
20. Paul I.A., Trullas R., Skolnick P., Nowak G. Down-regulation of cortical β-adrenoceptors by chronic treatment with functional NMDA antagonists. Psychopharmacology. 106:1992;285-287.
21. Peters S., Koh J., Choi D.W. Zinc selectively blocks the action of N-methyl-D-aspartate on cortical neurons. Science. 236:1987;589-593.
22. 3H]MK-801 binding to the N-methyl-D-aspartate receptor-ion channel complex by L-glutamate, glycine and polyamines. J. Neurochem. 51:1988;830-836.
23. Rogawski M.A. Therapeutic potential of excitatory amino acid antagonists: channel blockers and 2,3-benzodiazepines. Trends Pharmacol. 14:1993;325-331.
24. Rothman S.M., Olney J.W. Excitotoxicity and the NMDA receptor - still lethal after eight years. Trends Neurosci. 18:1995;57-58.
25. Scatton B. The NMDA receptor complex. Fundam. Clin. Pharmacol. 7:1993;389-400.
26. Vender J.R., Nair S.N., Lehmann J.C. NMDA receptors: the first decade. Exp. Opin. Invest. Drugs. 3:1994;341-354.
27. Vender J.R., Nair S.N., lehmann J.C. Pharmacotherapeutic potential for compounds acting at NMDA receptors: update 1995. Exp. Opin. Invest. Drugs. 4:1995;475-485.
28. Wong E.H.F., Kemp J.A., Priestley T., Knight G.N., Woodruff G.N., Iversen L.L. The anticonvulsant MK-801 is a potent N-methyl-D-aspartate antagonist. Proc. natn. Sci. U.S.A. 83:1986;7104-7108.